I am a pulmonary & critical care physician-scientist whose interests focus on the intersection between clinical risk-prediction models and genomic markers to improve pulmonary fibrosis outcomes.
Pulmonary fibrosis is a destructive interstitial lung disease characterized by profound scarring. In severe pulmonary fibrosis, death generally ensues within three to five years. Recent genomic advances have identified factors that influence heterogeneity and prognosis in pulmonary fibrosis. However, healthcare disparities and the exclusion of major racial groups from these genetic studies limits the generalizability of their findings. My work leverages advanced statistical techniques to improve the delivery of high-quality care in patients with fibrotic lung diseases. Much of my research is aimed at identifying improved practical strategies to optimize pharmacotherapy in patients with pulmonary fibrosis.
The main thrust of my work is currently on utilizing genetic data from diverse races to improve clinical decision-making and outcomes for all patients with pulmonary fibrosis.
Delving Deeper into Genotypic-Phenotypic Associations in Idiopathic Pulmonary Fibrosis.
Delving Deeper into Genotypic-Phenotypic Associations in Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc. 2025 Feb 12.
PMID: 39938064
Genome-wide association study of Idiopathic Pulmonary Fibrosis susceptibility using clinically-curated European-ancestry datasets.
Genome-wide association study of Idiopathic Pulmonary Fibrosis susceptibility using clinically-curated European-ancestry datasets. medRxiv. 2025 Feb 02.
PMID: 39974050
Accelerated epigenetic aging worsens survival and mediates environmental stressors in fibrotic interstitial lung disease.
Accelerated epigenetic aging worsens survival and mediates environmental stressors in fibrotic interstitial lung disease. Eur Respir J. 2025 Jan 30.
PMID: 39884761
Impact of Environmental Exposures on the Development and Progression of Fibrotic Interstitial Lung Disease.
Impact of Environmental Exposures on the Development and Progression of Fibrotic Interstitial Lung Disease. Am J Respir Crit Care Med. 2025 Jan 02.
PMID: 39745380
Identification of progressive pulmonary fibrosis: consensus findings from a modified Delphi study.
Identification of progressive pulmonary fibrosis: consensus findings from a modified Delphi study. Respir Res. 2024 Dec 31; 25(1):448.
PMID: 39741294
Single-Cell Analysis Reveals Novel Immune Perturbations in Fibrotic Hypersensitivity Pneumonitis.
Single-Cell Analysis Reveals Novel Immune Perturbations in Fibrotic Hypersensitivity Pneumonitis. Am J Respir Crit Care Med. 2024 Nov 15; 210(10):1252-1266.
PMID: 38924775
Quantitative CT Scan Analysis in Rheumatoid Arthritis-Related Interstitial Lung Disease.
Quantitative CT Scan Analysis in Rheumatoid Arthritis-Related Interstitial Lung Disease. Chest. 2024 Nov 09.
PMID: 39528110
Rare variants and survival of patients with idiopathic pulmonary fibrosis.
Rare variants and survival of patients with idiopathic pulmonary fibrosis. medRxiv. 2024 Oct 15.
PMID: 39484282
Biological Age, Chronological Age, and Survival in Pulmonary Fibrosis: A Causal Mediation Analysis.
Biological Age, Chronological Age, and Survival in Pulmonary Fibrosis: A Causal Mediation Analysis. Am J Respir Crit Care Med. 2024 Sep 01; 210(5):639-647.
PMID: 38843133
Potential of phosphodiesterase 4B inhibitors in the treatment of interstitial lung disease associated with autoimmune diseases.
Potential of phosphodiesterase 4B inhibitors in the treatment of interstitial lung disease associated with autoimmune diseases. Clin Exp Rheumatol. 2025 Jan; 43(1):119-125.
PMID: 39212123